Ernstoff, M.D. Taussig Cancer Institute R-35 Cleveland Clinic Foundation 9500 Euclid Ave Cleveland, OH 44195 216-444-0888 216-444-9464 ernstom@ccf.org Brent Hanks, M.D. Duke University 919-684-1995 919-684-1818 brent.hanks@duke.edu Keith Delman, M.D. Emory University 404-778-3303 kdelman@emory.edu David Lawson, M.D. Emory University 404-778-1900 dlawson@emory.edu Participation in the protocol is limited to the institutions and inve stigators listed above. NCI Protocol #: CITN-04 Version Date: 27 Jan 2016 2 Statistician: Study Coordinator: N/A Zoe Moodie, Ph.D. Fred Hutchinson Cancer Research Center 1100 Fairview Ave. N., M2-200 Seattle, WA 98109-1024 206-667-7077 zoe@fhcrc.org Responsible Research Nurse: N/A Responsible Data Manager: N/A NCI Supplied Agent(s): N/A Non-NCI Supplied Agent(s)/Supplier(s): Indoleamine 2,3, dioxygenase-1 (IDO1) inhibitor (INCB024360), NSC #766086, Incyte Corporation MELITAC 12.1 vaccine, (12 Melanoma Peptid es from MDP and CTA (12MP), NSC #728925, and Peptide-Tet, NSC #728927), University of Virginia Montanide ISA-51 VG, NSC #737063/, SEPPIC IND Sponsor: Fred Hutchinson Cancer Research Ce nter, Cancer Immunotherapy Trials Network (CITN) – IND # 15691 Protocol Type / Version # / Version Date: Amendment 8/Version 1.0/ 27 Jan 2016 NCI Protocol #: CITN-04 Version Date: 27 Jan 2016 3 CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT INFORMATION To submit site registration documents: For patient enrollments: Submit study data CTSU Regulatory Office 1818 Market Street, Suite 1100 Philadelphia, PA 19103 Phone – 1-866-651-CTSU Fax – 215-569-0206 Please refer to the patient enrollment section for instructions on using the OPEN system. Data collection for this study will be done exclusively through Medidata Rave.